Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine

被引:25
作者
Yamamoto, J
机构
[1] Pharmacology Section, Taiho Pharmaceutical Co. Ltd., 224-2, Ebi., Hiraishi, Kawauchi-cho
关键词
schizophrenia; animal model; EEG power spectra; cortex; hippocampus; methamphetamine; cocaine; phencyclidine; rabbit;
D O I
10.1007/s002130050306
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cortical and hippocampal EEGs in animal models of schizophrenia were compared to those obtained with psychotomimetics or antipsychotic agents by utilizing power spectral analysis. Models of positive schizophrenic symptoms were created with methamphetamine (MAP) and cocaine, and a model of both negative and positive symptoms was created with PCP MAP caused a prolonged decrease in the cortical EEG power spectra, cocaine caused a marked decrease for a short time, and PCP produced no significant changes. In the hippocampal spectra, MAP induced a marked increase in the T2(6.0-7.9 Hz)/T1(4.0-5.9 Hz) ratio. PCP caused a decrease of this ratio after an initial increase, and cocaine produced no significant change. (An increase in the T2/T1 ratio represents a shift of theta waves to higher frequencies.) Since apomorphine (a DA agonist) and MK-801 (an NMDA antagonist) caused the T2/T1 ratio to increase, positive schizophrenic symptoms caused by MAP may be related to the DA and NMDA systems. 3-PPP (a sigma agonist) caused biphasic changes similar to those induced by PCP. Haloperidol and chlorpromazine caused a decrease of the T2/T1 ratio. These results indicate that cortical and hippocampal EEG power spectra (especially the hippocampal T2/T1 ratio) can be used to characterize both qualitatively and quantitatively models of schizophrenia.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 32 条
[1]  
AKIYAMA K, 1990, CLIN NEUROPHARMAC S2, V13, P587
[2]   SELECTIVITY OF RELEASE OF NOREPINEPHRINE, DOPAMINE AND 5-HYDROXYTRYPTAMINE BY AMPHETAMINE IN VARIOUS REGIONS OF RAT-BRAIN [J].
AZZARO, AJ ;
RUTLEDGE, CO .
BIOCHEMICAL PHARMACOLOGY, 1973, 22 (22) :2801-2813
[3]   THE ROLE OF SEROTONIN IN SCHIZOPHRENIA [J].
BLEICH, A ;
BROWN, SL ;
KAHN, R ;
VANPRAAG, HM .
SCHIZOPHRENIA BULLETIN, 1988, 14 (02) :297-315
[4]   INTERACTIONS BETWEEN GLUTAMATERGIC AND MONOAMINERGIC SYSTEMS WITHIN THE BASAL GANGLIA - IMPLICATIONS FOR SCHIZOPHRENIA AND PARKINSONS-DISEASE [J].
CARLSSON, M ;
CARLSSON, A .
TRENDS IN NEUROSCIENCES, 1990, 13 (07) :272-276
[5]   THE SIGMA-RECEPTOR - A NOVEL SITE IMPLICATED IN PSYCHOSIS AND ANTIPSYCHOTIC DRUG EFFICACY [J].
DEUTSCH, SI ;
WEIZMAN, A ;
GOLDMAN, ME ;
MORIHISA, JM .
CLINICAL NEUROPHARMACOLOGY, 1988, 11 (02) :105-119
[6]   DIFFERENTIAL-EFFECTS OF THE NEW ANTIPSYCHOTIC RISPERIDONE ON SLEEP AND WAKEFULNESS IN THE RAT [J].
DUGOVIC, C ;
WAUQUIER, A ;
JANSSEN, PAJ .
NEUROPHARMACOLOGY, 1989, 28 (12) :1431-1433
[7]  
ELLINWOOD EH, 1990, CLIN NEUROPHARMAC S2, V13, P589
[8]   STUDIES ON ELECTROENCEPHALOGRAM (EEG) IN RATS SUGGEST THAT MODERATE DOSES OF COCAINE OR D-AMPHETAMINE ACTIVATE D-1 RATHER THAN D-2 RECEPTORS [J].
FERGER, B ;
KROPF, W ;
KUSCHINSKY, K .
PSYCHOPHARMACOLOGY, 1994, 114 (02) :297-308
[9]   NEUROCHEMICAL INTERACTIONS OF COCAINE WITH DOPAMINERGIC SYSTEMS [J].
GALLOWAY, MP .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1988, 9 (12) :451-454
[10]  
HERRLIN GPL, 1990, CLIN NEUROPHARMAC S2, V13, P265